ClearPoint Neuro (CLPT) FCF Margin (2011 - 2026)

ClearPoint Neuro has disclosed FCF Margin across 15 years of filings, most recently posting 71.01% for Q1 2026.

• FCF Margin for Q1 2026 came in at 71.01%, up 389.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 65.69% (down 2927.0% YoY), and the FY2025 annual result was 66.06%, down 3667.0% from the prior year.
• FCF Margin came in at 71.01% for Q1 2026 at ClearPoint Neuro, up from 116.27% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 14.91% in Q3 2024 to a low of 116.27% in Q4 2025.
• The 5-year median for FCF Margin is 59.99% (2022), against an average of 59.83%.
• Across the five-year window, FCF Margin soared 5682 bps in 2024 and tumbled 9689 bps in 2025, its largest moves.
• ClearPoint Neuro's FCF Margin stood at 59.99% in 2022, then surged by 71 bps to 17.47% in 2023, then retreated by 11 bps to 19.38% in 2024, then sank by 500 bps to 116.27% in 2025, then jumped by 39 bps to 71.01% in 2026.
• The last three FCF Margin figures came in at 71.01% (Q1 2026), 116.27% (Q4 2025), and 37.47% (Q3 2025), per Business Quant data.